Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Freimut H Schilling"'
Autor:
Julia Beckhaus, Svenja Boekhoff, Katrin Scheinemann, Freimut H Schilling, Gudrun Fleischhack, Gerhard Binder, Brigitte Bison, Torsten Pietsch, Carsten Friedrich, Hermann L Müller
Publikováno v:
Endocrine Connections, Vol 12, Iss 12, Pp 1-11 (2023)
Background: Craniopharyngiomas (CPs) are rare embryonic tumors. Clinical presentation and outcome of patients perinatally diagnosed with congenital CP (cCP) are not clear and refer mainly to a few case reports in the literature. The aim of this study
Externí odkaz:
https://doaj.org/article/10df589f694243d0bdd2893c38ea7ce4
Autor:
José M. Bastida, Stefano Malvestiti, Doris Boeckelmann, Verónica Palma-Barqueros, Mira Wolter, María L. Lozano, Hannah Glonnegger, Rocío Benito, Carlo Zaninetti, Felix Sobotta, Freimut H. Schilling, Neil V. Morgan, Kathleen Freson, José Rivera, Barbara Zieger
Publikováno v:
Cells, Vol 11, Iss 20, p 3223 (2022)
The GATA1 transcription factor is essential for normal erythropoiesis and megakaryocytic differentiation. Germline GATA1 pathogenic variants in the N-terminal zinc finger (N-ZF) are typically associated with X-linked thrombocytopenia, platelet dysfun
Externí odkaz:
https://doaj.org/article/f0d19dacc42049e4a460cf0a87e336a5
Autor:
Géraldine L. P. Bono, Markus Lehner, Freimut H. Schilling, Nikolai Stahr, Miriam Nowack, Philipp O. Szavay
Publikováno v:
European Journal of Pediatric Surgery Reports, Vol 08, Iss 01, Pp e48-e51 (2020)
Calcifying fibrous tumor (CFT) is a benign tumor entity which can present in a variety of different sites. Till date, eight cases with a mediastinal manifestation have been published in literature. Surgical removal is the treatment of choice for this
Externí odkaz:
https://doaj.org/article/f9b58927bdb14b2983bec4a0269d850e
Autor:
Freimut H. Schilling
Publikováno v:
Pädiatrie up2date. 16:79-92
Autor:
Barbara Hero, Joern Treuner, Claudia Spix, Rudolf Erttmann, Joerg Michaelis, Freimut H. Schilling, Angela Ernst, Frank Berthold
Publikováno v:
JNCI Cancer Spectrum
Background Neuroblastoma screening aims to reduce neuroblastoma-related mortality. A controlled trial showed no reduction in stage 4 disease incidence and preliminary mortality data. This article presents epidemiologic and clinical data 20 years afte
Autor:
Nicolas Waespe, Marc Ansari, Jean-Pierre Bourquin, Maja Beck-Popovic, Fabiën N. Belle, Jochen Rössler, Shelagh Redmond, Ben D. Spycher, Nicolas von der Weid, Jeanette Greiner, Katrin Scheinemann, Claudia E. Kuehni, Christina Schindera, Freimut H. Schilling, Pierluigi Brazzola
Publikováno v:
European journal of cancer, Vol. 145 (2021) pp. 71-80
Waespe, Nicolas; Belle, Fabiën N.; Redmond, Shelagh; Schindera, Christina; Spycher, Ben D.; Rössler, Jochen; Ansari, Marc; Kuehni, Claudia E. (2021). Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer-A national cohort study. European journal of cancer, 145, pp. 71-80. Elsevier 10.1016/j.ejca.2020.11.042
Waespe, Nicolas; Belle, Fabiën N.; Redmond, Shelagh; Schindera, Christina; Spycher, Ben D.; Rössler, Jochen; Ansari, Marc; Kuehni, Claudia E. (2021). Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer-A national cohort study. European journal of cancer, 145, pp. 71-80. Elsevier 10.1016/j.ejca.2020.11.042
Background: Childhood cancer patients are at increased risk of second primary neoplasms (SPNs). We assessed incidence and risk factors for early SPNs with a focus on cancer predisposition syndromes (CPSs). Patients and methods: This cohort study used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cacba93b3aead1ce124526b0cc6cbdda
https://doi.org/10.5167/uzh-213020
https://doi.org/10.5167/uzh-213020
Autor:
Freimut H. Schilling, Carolina Rosswog, Holger Christiansen, Thorsten Simon, Barbara Hero, Michael C. Frühwald, Irene Schmid, Angela Ernst, Nadine Hemstedt, Matthias Fischer, Frank Berthold, B. Fröhlich, Thomas Klingebiel
Publikováno v:
Pediatric bloodcancerREFERENCES. 68(8)
Introduction The survival of children with stage 4(M) neuroblastoma without MYCN amplification and below the age of 18 months is considered better than the still dismal outcome of older high-risk neuroblastoma patients. This study analyzes the impact
Autor:
Benoît Guillet, Jan Blatny, Jennifer Doralt, Srilatha Tangada, Gerald Spotts, Bénédicte Wibaut, Freimut H. Schilling, Andras Nagy, Jimena Goldstine, Werner Engl, Jayashree Motwani
Publikováno v:
Haemophilia
Haemophilia, 2020, 26 (3), pp.478-486. ⟨10.1111/hae.13997⟩
Haemophilia, Wiley, 2020, 26 (3), pp.478-486. ⟨10.1111/hae.13997⟩
Haemophilia, 2020, 26 (3), pp.478-486. ⟨10.1111/hae.13997⟩
Haemophilia, Wiley, 2020, 26 (3), pp.478-486. ⟨10.1111/hae.13997⟩
International audience; Introduction - Antihaemophilic factor (recombinant) (rAHF; ADVATE ) is approved for prophylaxis and treatment of bleeding in children and adults with haemophilia A. Reconstitution in 2 mL sterile water for injection instead of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3ed319c05fc86c4468abc086150d49
https://univ-rennes.hal.science/hal-02565726
https://univ-rennes.hal.science/hal-02565726
Publikováno v:
Hamostaseologie. 40(1)
Patients suffering from haemophilia encounter various phases in life, in which individual needs, life situations, and self- and disease perception change rapidly. One of these phases spans from the beginning of puberty until early adulthood, in which
Autor:
Christian P. Kratz, D. von Schweinitz, Michael C. Frühwald, T. Klingebiel, D. Dilloo, Andreas Faldum, Frank Berthold, Ruth Volland, Angelika Eggert, Thorsten Simon, Roswitha Schumacher-Kuckelkorn, Bernhard Kremens, Ivo Leuschner, Matthias Fischer, Angela Ernst, Freimut H. Schilling, Joachim Boos, Barbara Krug, Matthias Schmidt, Barbara Hero, Günter Henze, Rene Schmidt, Jessica Theissen
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(3)
Background Long-term survival of high-risk neuroblastoma patients is still below 50% despite intensive multimodal treatment. This trial aimed to address whether the addition of two topotecan-containing chemotherapy courses compared to standard induct